

TURNOVER INCREASES BY 50 % AND PROFIT DOUBLES

JANUARY-MARCH 2011

- **NET SALES** amounted to 23.9 million SEK (15.9).
- **EBIT** amounted to 6.8 million SEK (3.2).
- **PROFIT AFTER TAX** amounted to 5.1 million SEK (2.4).
- **EARNINGS PER SHARE** amounted to 0.55 SEK (0.26).
- **TOTAL CASH FLOW** amounted to -4.7 million SEK (1.7).

IMPORTANT EVENTS DURING THE FIRST QUARTER:

- Royalty proceeds from ProViva increased by 10 percent compared to the first quarter 2010.
- Proceeds from Dietary Supplements increased by 125 percent and amounted to 8.3 million SEK (3.7).
- New distribution agreement with Ta'am Teva Altman, Israel, regarding dietary supplements based on *Lp299v*.
- Probi has repurchased 150,000 treasury shares for a value of 6.9 million SEK.

CEO'S COMMENTS:

"It is a sign of strength that we grew by 50 percent at the same time as profits doubled. 2011 was our best year ever and the positive trend continues. Our agreements with Danone and the successful launch of our own brands are two solid platforms upon which further growth can be built," says Michael Oredsson, CEO of Probi.

FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO Probi, phone: +46 (0)46 286 89 23 or +46 (0)707 18 89 30,
e-mail: michael.oredsson@probi.se

The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was submitted for disclosure on 27 April 2011 at 08:45 (cet)

OM PROBI

Probi är en ledande aktör inom probiotisk forskning och utveckling av effektiv och väldokumenterad probiotika. Forskningsområdena är: mage och tarm, immunförsvar, metabola syndromet samt stress och återhämtning. Probis kunder är ledande företag inom segmenten functional food och kosttillskott. Totala intäkter 2010 var 81,1 miljoner SEK, varav merparten utgjordes av royaltyintäkter. Probis aktie är noterad på Nasdaq OMX Stockholm, Small Cap. Probi har cirka 4 200 aktieägare. Läs mer på www.probi.se

